Saturn V Capital Management LP
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 13, 2025), Saturn V Capital Management LP reported 24 stock positions worth $246.8 million. Its top holding was Jazz Pharmaceuticals (JAZZ) at 8.9% of the portfolio, followed by Disc Medicine (IRON, 8.5%) and Amylyx Pharmaceuticals (AMLX, 8.5%). Compared with Q1 2025, it opened 5 new positions, sold out of 2, added to 10 and reduced 9. The biggest buy was a new position in Jazz Pharmaceuticals (JAZZ) and the biggest sale Ascendis Pharma A/S (ASND, shares −81%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001964437
- Portfolio Value
- $246.8M (Q2 2025)
- SEC Filing
- 0001964437-25-000008 ↗ filed Aug 13, 2025
Holdings Value
Holdings 24 stocks · $246.8M
| JAZZ Jazz Pharmaceuticals PLC | 8.90% | 206,952 | $22.0M | New |
| IRON Disc Medicine Inc. | 8.50% | 396,115 | $21.0M | Reduce -23.6% |
| AMLX Amylyx Pharmaceuticals Inc. | 8.47% | 3,260,570 | $20.9M | Add +34.4% |
| PCVX Vaxcyte Inc. | 7.17% | 544,221 | $17.7M | Add +134.3% |
| COGT Cogent Biosciences Inc. | 6.69% | 2,297,524 | $16.5M | Add +55.2% |
| CELC Celcuity Inc. | 6.41% | 1,185,520 | $15.8M | Add +8.4% |
| CGON CG Oncology Inc. | 6.18% | 586,647 | $15.3M | Add +1.6% |
| XENE Xenon Pharmaceuticals Inc. | 5.94% | 468,364 | $14.7M | Add +13.2% |
| DYN Dyne Therapeutics Inc. | 5.62% | 1,455,429 | $13.9M | New |
| MLTX Moonlake Immunotherapeutics | 5.56% | 290,784 | $13.7M | Reduce -15.4% |
| MRUS Merus NV | 4.78% | 224,260 | $11.8M | Reduce -30.6% |
| CNTA Centessa Pharmaceuticals Ltd. | 4.22% | 793,327 | $10.4M | Add +76.8% |
| LENZ Lenz Therapeutics Inc. | 4.07% | 342,312 | $10.0M | New |
| NBIX Neurocrine Biosciences Inc. | 2.96% | 58,181 | $7.3M | New |
| OCUL Ocular Therapeutix Inc. | 2.74% | 728,576 | $6.8M | Add +21.8% |
| ASND Ascendis Pharma A/S | 2.67% | 38,191 | $6.6M | Reduce -80.8% |
| ARGX Argenx SE - ADR | 2.30% | 10,285 | $5.7M | Reduce -25.8% |
| ABVX Abivax SA-ADR | 1.93% | 622,479 | $4.8M | Add +12.6% |
| SNDX Syndax Pharmaceuticals Inc. | 1.90% | 500,551 | $4.7M | Reduce -51.9% |
| NAMS Newamsterdam Pharma Co. NV | 1.62% | 220,695 | $4.0M | Add +89.7% |
| CTNM Contineum Therapeutics Inc. Class A | 0.51% | 319,348 | $1.3M | Reduce -43.1% |
| REPL Replimune Group Inc. | 0.49% | 128,917 | $1.2M | New |
| KALV Kalvista Pharmaceuticals Inc. | 0.29% | 62,793 | $710K | Reduce -75.4% |
| SLN Silence Therapeutics PLC-ADR | 0.08% | 34,737 | $201K | Reduce -95.3% |
Portfolio Sells Q1 2025 → Q2 2025
| ASND Ascendis Pharma A/S | Reduce -80.8% | 2.67% | −13.00 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -51.9% | 1.90% | −4.56 |
| IRON Disc Medicine Inc. | Reduce -23.6% | 8.50% | −4.48 |
| MRUS Merus NV | Reduce -30.6% | 4.78% | −2.08 |
| ARGX Argenx SE - ADR | Reduce -25.8% | 2.30% | −1.84 |
| CTNM Contineum Therapeutics Inc. Class A | Reduce -43.1% | 0.51% | −1.46 |
| MLTX Moonlake Immunotherapeutics | Reduce -15.4% | 5.56% | −1.22 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -75.4% | 0.29% | −1.20 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −1.00 |
| SLN Silence Therapeutics PLC-ADR | Reduce -95.3% | 0.08% | −0.96 |
| INZY Inozyme Pharma Inc. | Sold out | 0.00% | −0.23 |
Portfolio Buys Q1 2025 → Q2 2025
| JAZZ Jazz Pharmaceuticals PLC | New | 8.90% | +8.90 |
| DYN Dyne Therapeutics Inc. | New | 5.62% | +5.62 |
| AMLX Amylyx Pharmaceuticals Inc. | Add +34.4% | 8.47% | +4.14 |
| LENZ Lenz Therapeutics Inc. | New | 4.07% | +4.07 |
| NBIX Neurocrine Biosciences Inc. | New | 2.96% | +2.96 |
| PCVX Vaxcyte Inc. | Add +134.3% | 7.17% | +2.74 |
| COGT Cogent Biosciences Inc. | Add +55.2% | 6.69% | +2.21 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +76.8% | 4.22% | +0.97 |
| CELC Celcuity Inc. | Add +8.4% | 6.41% | +0.83 |
| OCUL Ocular Therapeutix Inc. | Add +21.8% | 2.74% | +0.53 |
| REPL Replimune Group Inc. | New | 0.49% | +0.49 |
| NAMS Newamsterdam Pharma Co. NV | Add +89.7% | 1.62% | +0.42 |
| ABVX Abivax SA-ADR | Add +12.6% | 1.93% | +0.19 |
| CGON CG Oncology Inc. | Add +1.6% | 6.18% | −0.96 |
| XENE Xenon Pharmaceuticals Inc. | Add +13.2% | 5.94% | −1.06 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $697.5M | AMLX, ALMS, ABVX, PCVX, IMMX |
| Q1 2026 | 21 | $552.2M | ALMS, AMLX, ABVX, PCVX, PHVS |
| Q4 2025 | 20 | $544.9M | ABVX, AMLX, COGT, JAZZ, PCVX |
| Q3 2025 | 17 | $456.0M | ABVX, AMLX, JAZZ, DYN, COGT |
| Q2 2025 | 24 | $246.8M | JAZZ, IRON, AMLX, PCVX, COGT |
| Q1 2025 | 21 | $198.2M | ASND, IRON, CGON, XENE, MRUS |
| Q4 2024 | 24 | $255.4M | IRON, ASND, MLTX, CGON, PCVX |
| Q3 2024 | 25 | $279.8M | ASND, IRON, PCVX, CGON, COGT |
| Q2 2024 | 26 | $264.6M | ARGX, IRON, CRNX, PCVX, ASND |
| Q1 2024 | 21 | $249.4M | CRNX, ARGX, CYTK, KALV, MRUS |